910575-44-9

Upstream product

• 866087-20-9 3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-oxo-propionic acid 
• 168196-87-0 2-benzyloxy-5-bromo-1,3-dimethylbenzene 
• 866087-19-6 (Z,E)-2-acetylamino-3-(4-benzyloxy-3,5-dimethyl-phenyl)-acrylic acid methyl ester 
• 100-44-7 benzyl chloride 

Downstream Products

• 866087-22-1 (R)-3-(4-Benzyloxy-3,5-dimethyl-phenyl)-2-hydroxy-propionic acid methyl ester 
• 866087-24-3 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 
• 866087-23-2 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910576-11-3 4-(2-oxo-1,2-dihydro-quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 
• 910576-10-2 4-(2-oxo-1,2-dihydro-quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910576-07-7 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910576-08-8 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 

Relevant academic research and scientific papers

2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS

The invention relates to novel CGRP antagonists of general formula (I), in which B, R1 and R2 are defined as cited in claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts, in addition to the hydrates of their salts, in particular their physiologically compatible salts, with inorganic or organic acids or bases. The invention also relates to medicaments containing said compounds, to their use and to a method for their production.

CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I) in which: R1, R2, R3, R4 and X are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts as well as the hydrates of the salts, in particular, their physiologically compatible salts with inorganic or organic acids and bases, and those compounds of general formula (I) in which one or more hydrogen atoms are replaced by deuterium. The invention also relates to medicaments containing these compounds, the use thereof, and to methods for producing them.